Julia Haller

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update

Retrieved on: 
Thursday, December 29, 2022
Diosynth, Clinical trial, BRVO, Partnership, Calendar, PDUFA, CHMP, Food, Therapy, Julia Haller, MD, Research, Diabetic retinopathy, BLA, Syringe, Injection, European Directive on Traditional Herbal Medicinal Products, Alliance Healthcare, Note, Patient, Visual impairment, Acquisition, GlobalData, AMD, Special Protection Area, Physician, Safety, FDA, Bevacizumab, Food and Drug Administration, MAA, Marketing, DME, Retina, AmerisourceBergen, Pharmaceutical industry, Life insurance, Security (finance), Medical device, EU

Approximately $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2.00.

Key Points: 
  • Approximately $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2.00.
  • “Our fiscal year 2022 laid a solid foundation for what we believe will be a transformational 2023.
  • Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and submitted them in December 2022.
  • Additionally, Outlook Therapeutics continues to explore potential strategic commercialization partners, such as the current partnership with Syntone Biopharma JV in China.

Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors

Retrieved on: 
Thursday, April 1, 2021
Biotechnology, Medical devices, Health, Pharmaceutical, Optical, Julia Haller, Haller, Ophthalmology

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.

Key Points: 
  • Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20210401005130/en/
    Renowned ophthalmologist and scientific leader Dr. Julia Haller has been appointed to the Board of Directors of Eyenovia.
  • (Photo: Business Wire)
    We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia, commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia.
  • I look forward to working with my fellow Eyenovia Board members and the leadership team to help create advances in the field.

Thomas Jefferson University Faculty Elected to National Academy of Medicine

Retrieved on: 
Tuesday, October 22, 2019
United States, Center City, Philadelphia, Wills Eye Hospital, American writers, Julia Haller, William Tasman, Thomas Jefferson University, Thomas Jefferson, Jefferson

PHILADELPHIA, Oct. 22, 2019 /PRNewswire/ -- Julia A. Haller, MD, Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital was elected to the National Academy of Medicine.

Key Points: 
  • PHILADELPHIA, Oct. 22, 2019 /PRNewswire/ -- Julia A. Haller, MD, Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital was elected to the National Academy of Medicine.
  • She is the fourth faculty member in Jefferson's history to be elected, and the first female.
  • "Dr. Haller is a trailblazer and her contributions to the field of ophthalmology have transformed research and care," said Mark Tykocinski MD, Provost and Executive Vice President for Academic Affairs at Thomas Jefferson University and the Anthony F. and Gertrude M. DePalma Dean, Sidney Kimmel Medical College at Thomas Jefferson University.
  • Jefferson (Philadelphia University + Thomas Jefferson University), home of the Sidney Kimmel Medical College, dates back to 1824 and today comprises 10 colleges and three schools offering 160 undergraduate programs and more than 7,800 students.

Wills Eye Hospital Named #1 Ophthalmology Training Program In America

Retrieved on: 
Monday, September 9, 2019
Center City, Philadelphia, Wills Eye Hospital, Ophthalmology, Health, Eye care, Julia Haller

PHILADELPHIA, Sept. 9, 2019 /PRNewswire/ -- Wills Eye Hospital is taking top honors again this year for the best residency training program in the USA for ophthalmologists.

Key Points: 
  • PHILADELPHIA, Sept. 9, 2019 /PRNewswire/ -- Wills Eye Hospital is taking top honors again this year for the best residency training program in the USA for ophthalmologists.
  • "Our world-renowned Wills Eye medical staff is deeply committed to the pillars of our mission: clinical care, education and research.
  • This honor coincides with the opening of the William Maul Measey Ophthalmic Surgical Training (MOST) Laboratory at the Hospital.
  • Wills Eye Hospital serves as the Department of Ophthalmology for Sidney Kimmel Medical College at Thomas Jefferson University and Jefferson Hospitals.

Wills Eye Hospital's Training in Ophthalmology Voted #1 Top Eye Residency Program in Nation

Retrieved on: 
Tuesday, December 11, 2018
Health, Medicine, Center City, Philadelphia, Wills Eye Hospital, Ophthalmology, Residency, Optometry, The University of Illinois Eye and Ear Infirmary, Julia Haller

The residency program consists of three years of training in all subspecialties of ophthalmology, following a post-medical school internship year.

Key Points: 
  • The residency program consists of three years of training in all subspecialties of ophthalmology, following a post-medical school internship year.
  • When asked what are the top five best features of the Wills Eye Residency Program, residents cite: the breadth and depth of ocular conditions treated at Wills Eye Hospital, the hands-on training experience with world-renowned faculty who staff clinics and surgery directly, the unique 24/7 eye-only Wills Eye Emergency Room, global involvement including the Wills International Resident Experience, and the special culture and family feeling of Wills Eye Hospital.
  • "We are so very proud of our residents, and prioritize our residency education program so highly here at Wills.
  • Wills Eye Hospital is a global leader in ophthalmology, established in 1832 as the nation's first hospital specializing in eye care.

Wills Eye Hospital Earns National Recognition for Excellence

Retrieved on: 
Tuesday, August 14, 2018
Health, Center City, Philadelphia, Wills Eye Hospital, Medicine, Ophthalmology, Optometry, Julia Haller

Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, said, "What we can do on behalf of our patients drives every decision we make at Wills Eye Hospital.

Key Points: 
  • Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, said, "What we can do on behalf of our patients drives every decision we make at Wills Eye Hospital.
  • Established the Vickie and Jack Farber Vision Research Center at Wills Eye dedicated to the advancement of vision science.
  • Wills Eye Hospital is a global leader in ophthalmology, established in 1832 as the nation's first hospital specializing in eye care.
  • Wills Eye also has a network of seven multi-specialty, ambulatory surgery centers throughout the tri-state area.